CJC-1295 No DAC + Ipamorelin

CJC-1295 No DAC + Ipamorelin Blend is Signal Labs' dual growth hormone axis research preparation, containing CJC-1295 No DAC (5mg) and Ipamorelin (5mg) co-lyophilised in a single vial. This combination simultaneously targets both major GH-releasing receptor systems on pituitary somatotrophs — GHRHR (Growth Hormone Releasing Hormone Receptor) via CJC-1295 No DAC and GHS-R1a (Growth Hormone Secretagogue Receptor 1a) via Ipamorelin — through entirely distinct intracellular signalling cascades that produce additive to synergistic GH release.

CJC-1295 No DAC (MW 3367.9 g/mol) is a four-modification GHRH(1-29) analogue with D-Ala2, Gln8, Ala15, and Leu27 substitutions providing DPP-IV resistance and chemical stability. It activates GHRHR through Gs/cAMP/PKA signalling: adenylyl cyclase activation raises intracellular cAMP, PKA phosphorylates CREB (driving GH gene transcription) and L-type calcium channels (promoting secretory granule exocytosis). The approximately 30-minute plasma half-life produces pulsatile, defined-duration GHRHR stimulation without the continuous occupancy of the DAC variant.

Ipamorelin (MW 711.85 g/mol) is a synthetic pentapeptide (Aib-His-D-2-Naphthylalanine-D-Phe-Lys-NH2) and the most GHS-R1a-selective GHRP characterised. It activates GHS-R1a through Gq/11/PLCbeta/IP3/calcium signalling: IP3-mediated calcium release from the ER and DAG/PKC activation drive GH granule exocytosis through calcium-sensitive SNARE proteins. Ipamorelin's selectivity for GHS-R1a without off-target ACTH, prolactin, or aldosterone stimulation — established by Raun et al. (European Journal of Endocrinology, 1998) — distinguishes it from earlier GHRPs (GHRP-2, GHRP-6) and makes it the preferred GHS-R1a tool for clean dual-receptor research.

The synergistic GH release from combined GHRHR + GHS-R1a activation is mechanistically explained by the complementary convergence of two independent second messenger systems. cAMP/PKA (from GHRHR) and IP3/calcium/PKC (from GHS-R1a) both contribute to GH granule exocytosis through different molecular effectors — activating both simultaneously exceeds what either alone achieves. Additionally, Ipamorelin suppresses hypothalamic somatostatin release (mimicking ghrelin's somatostatin-inhibiting activity), removing the primary inhibitory brake on GHRHR-mediated GH secretion and further amplifying the combined response.

GH pulse characterisation with the blend measures: peak GH concentration by ELISA (sampling every 15-30 minutes); GH pulse duration (time from peak to return to baseline); and downstream IGF-1 production (collected 4-8 hours post-administration, reflecting the lag between GH pulse and hepatic IGF-1 synthesis). For comparison with individual compounds, use separately purchased CJC-1295 No DAC (5mg) and Ipamorelin (5mg) from Signal Labs.

Molar content note: at the 5mg/5mg mass ratio, CJC-1295 No DAC provides approximately 1.5 nmol and Ipamorelin provides approximately 7 nmol — a molar ratio of approximately 1:5. Researchers requiring equimolar ratios should calculate reconstitution volumes accordingly using the individual compounds.

Total vial content: 10mg (5mg CJC-1295 No DAC + 5mg Ipamorelin). Reconstitute in bacteriostatic water. Both components are freely water-soluble. Store lyophilised at -20°C. For laboratory and analytical research purposes only.

GH pulse characterisation endpoints: peak GH by ELISA (15-30 minute sampling intervals for first 2 hours); downstream IGF-1 production at 4-8 hours (hepatic IGF-1 synthesis lag); and somatostatin suppression monitoring by measuring hypothalamic somatostatin mRNA (qPCR) in parallel preparations. For individual compound mechanistic studies, CJC-1295 No DAC (5mg) and Ipamorelin (5mg) are each available separately from Signal Labs. Total vial: 10mg (5mg + 5mg). Reconstitute in bacteriostatic water. Store lyophilised at -20°C. For laboratory and analytical research purposes only.